Access to Genetic Testing in Underserved Patients With Cancer

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Southern California

About this trial

This study compares the experiences of people who receive information about genetic testing from a computer-generated character to patients who receive information from a human genetics healthcare provider. Patients with cancer are increasingly recommended for genetic testing as standard of care. Multiple factors contribute to low usage of genetic testing but for many patients the lack of access to genetic counseling and testing is an important and flexible factor. Lack of access is especially relevant to racial/ethnic minority patients and those living in non-metropolitan rural settings who are frequently cared for at safety-net hospitals with limited genetics services. Alternative delivery models are necessary to improve rates of access to genetic testing in patients with cancer. Health information technology is under used by genetics providers. A patient-facing relational agent (PERLA) will provide pre-test genetics education in both English and Spanish across two clinical settings to facilitate more timely access to genetic testing. Using the PERLA intervention may help researchers learn different ways to provide education about genetic testing to patients with cancer compared to usual care.

Eligibility criteria

Qualifiers

Age > 18 years old

Epithelial ovarian cancer

Exocrine pancreatic cancer

Metastatic or high or very high-risk prostate cancer

Disqualifiers

Patients who cannot provide informed consent

Patients who cannot see, read, or write

Patients who have the cancer and clinical characteristics defined in the inclusion criteria, but who do not speak English or Spanish

Patients with none of the listed cancer diagnoses and clinical characteristics

Trial design

Treatments tested in this trial

  • Best Practice
  • Educational Intervention
  • Electronic Health Record Review
  • Genetic Counseling
  • Interview
  • Survey Administration

Treatment groups

800 Participants
are divided into 2 treatment groups

Sponsors and collaborators

University of Southern California

Lead sponsor

National Cancer Institute (NCI)

Collaborator

Northeastern University

Collaborator

Dana-Farber Cancer Institute

Collaborator